论文部分内容阅读
目的观察吉西他滨联合顺铂方案治疗晚期非小细胞肺癌的近期疗效与不良反应。方法采用GP方案治疗晚期NSCLC45例:吉西他滨1.0/m2,第1、8天,静脉滴注;顺铂25 mg/m2,第1~3天,静脉滴注,21 d为1个周期,至少治疗2个周期。结果可评价疗效45例,完全缓解(CR)1例(2.2%),部分缓解(PR)20例(44.4%),稳定(SD)15例(33.3%),进展(PD)9例(20%)。总有效率(CR+PR)46.7%(21/45),肿瘤控制率(CR+PR+SD)80%(36/45)。中位生存期11.8个月。不良反应主要为可耐受的骨髓抑制、恶心呕吐、脱发为常见、无化疗相关死亡。结论吉西他滨与顺铂联合方案疗效较好,不良反应较轻可耐受,是晚期NSCLC的有效治疗方案。
Objective To observe the short-term efficacy and side effects of gemcitabine combined with cisplatin in the treatment of advanced non-small cell lung cancer. Methods Forty-five patients with advanced NSCLC were treated with GP regimen: gemcitabine 1.0 / m2 on days 1 and 8, intravenous drip on days 1 and 8, cisplatin 25 mg / m2 on days 1 to 3, and intravenous drip on day 21 for at least one cycle 2 cycles. Results A total of 45 patients were evaluated for efficacy, complete remission (CR) in 1 case (2.2%), partial remission (PR) in 20 cases (44.4%), stable (SD) in 15 cases (33.3%) and progression (PD) in 9 cases %). The total effective rate (CR + PR) was 46.7% (21/45), and the tumor control rate (CR + PR + SD) was 80% (36/45). The median survival was 11.8 months. Adverse reactions were mainly tolerable myelosuppression, nausea and vomiting, hair loss is common, no chemotherapy-related deaths. Conclusion The combination of gemcitabine and cisplatin has good curative effect and mild side effects, which is an effective treatment for advanced NSCLC.